Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Langerhans Cell Histiocytosis”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 0 results

Large-scale testing (Phase 3)UnknownNCT02631109
What this trial is testing

L-DEP Regimen as a Salvage Therapy for Refractory Epstein Barr Virus-induced Hemophagocytic Lymphohistiocytosis

Who this might be right for
Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital 120
Large-scale testing (Phase 3)UnknownNCT05315336
What this trial is testing

L-DEP/DEP Regimen and PD-1 Antibody as a Treatment for Relapse/Refractory EBV-HLH

Who this might be right for
Hemophagocytic Lymphohistiocytosis
Beijing Friendship Hospital 50
Early research (Phase 1)Study completedNCT00890747
What this trial is testing

Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Undifferentiated Leukemia+82 more
National Cancer Institute (NCI) 42
Early research (Phase 1)Enrolling By InvitationNCT06902792
What this trial is testing

Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

Who this might be right for
Histiocytosis, Langerhans-Cell
Second Affiliated Hospital of Wenzhou Medical University 6
Testing effectiveness (Phase 2)Study completedNCT03213678
What this trial is testing

Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)

Who this might be right for
Advanced Malignant Solid NeoplasmAnn Arbor Stage III Non-Hodgkin LymphomaAnn Arbor Stage IV Non-Hodgkin Lymphoma+30 more
National Cancer Institute (NCI) 18